280 related articles for article (PubMed ID: 33158772)
1. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.
Porcu P; Hudgens S; Horwitz S; Quaglino P; Cowan R; Geskin L; Beylot-Barry M; Floden L; Bagot M; Tsianakas A; Moskowitz A; Huen A; Dreno B; Dalle S; Caballero D; Leoni M; Dale S; Herr F; Duvic M
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):97-105. PubMed ID: 33158772
[TBL] [Abstract][Full Text] [Related]
2. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH; Bagot M; Pinter-Brown L; Rook AH; Porcu P; Horwitz SM; Whittaker S; Tokura Y; Vermeer M; Zinzani PL; Sokol L; Morris S; Kim EJ; Ortiz-Romero PL; Eradat H; Scarisbrick J; Tsianakas A; Elmets C; Dalle S; Fisher DC; Halwani A; Poligone B; Greer J; Fierro MT; Khot A; Moskowitz AJ; Musiek A; Shustov A; Pro B; Geskin LJ; Dwyer K; Moriya J; Leoni M; Humphrey JS; Hudgens S; Grebennik DO; Tobinai K; Duvic M;
Lancet Oncol; 2018 Sep; 19(9):1192-1204. PubMed ID: 30100375
[TBL] [Abstract][Full Text] [Related]
3. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
4. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
Lewis DJ; Rook AH
Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
[TBL] [Abstract][Full Text] [Related]
5. Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome.
Beylot-Barry M; Booken N; Weishaupt C; Scarisbrick J; Wu W; Rosen JP; Medley MC
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):311-316. PubMed ID: 35993803
[TBL] [Abstract][Full Text] [Related]
6. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.
McCaffrey S; Black RA; Nagao M; Sepassi M; Sharma G; Thornton S; Kim YH; Braverman J
J Med Internet Res; 2019 Jan; 21(1):e11302. PubMed ID: 30617041
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
Hirotsu KE; Neal TM; Khodadoust MS; Wang JY; Rieger KE; Strelo J; Hong E; Kim YH; Kwong BY
JAMA Dermatol; 2021 Jun; 157(6):700-707. PubMed ID: 33881447
[TBL] [Abstract][Full Text] [Related]
8. Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
Horwitz S; Zinzani PL; Bagot M; Kim YH; Moskowitz AJ; Porcu P; Dwyer K; Sun W; Herr FM; Scarisbrick J
Leuk Lymphoma; 2021 Dec; 62(13):3109-3118. PubMed ID: 34304674
[TBL] [Abstract][Full Text] [Related]
9. Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Grimm SE; Witlox W; Wolff R; Chalker A; Hiligsmann M; Wijnen B; Ahmadu C; Ryder S; Armstrong N; Duffy S; Syndikus I; Kleijnen J; Joore MA
Pharmacoeconomics; 2022 May; 40(5):509-518. PubMed ID: 34664200
[TBL] [Abstract][Full Text] [Related]
10. Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care.
Hawkins N; Muszbek N; Evans R; McNamara L; Jones T
J Comp Eff Res; 2023 Oct; 12(10):e230017. PubMed ID: 37642410
[No Abstract] [Full Text] [Related]
11. FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.
Kasamon YL; Chen H; de Claro RA; Nie L; Ye J; Blumenthal GM; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Dec; 25(24):7275-7280. PubMed ID: 31366601
[TBL] [Abstract][Full Text] [Related]
12. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
[No Abstract] [Full Text] [Related]
13. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.
Beylot-Barry M; Quereux G; Nardin C; Duval-Modeste AB; Dereure O; Dalac-Rat S; Dobos G; Pham-Ledard A; Ram-Wolff C; D'Incan M; Grange F; Braniste V; Bagot M
J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1777-1784. PubMed ID: 37113040
[TBL] [Abstract][Full Text] [Related]
15. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
Olsen EA; Whittaker S; Kim YH; Duvic M; Prince HM; Lessin SR; Wood GS; Willemze R; Demierre MF; Pimpinelli N; Bernengo MG; Ortiz-Romero PL; Bagot M; Estrach T; Guitart J; Knobler R; Sanches JA; Iwatsuki K; Sugaya M; Dummer R; Pittelkow M; Hoppe R; Parker S; Geskin L; Pinter-Brown L; Girardi M; Burg G; Ranki A; Vermeer M; Horwitz S; Heald P; Rosen S; Cerroni L; Dreno B; Vonderheid EC; ; ;
J Clin Oncol; 2011 Jun; 29(18):2598-607. PubMed ID: 21576639
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
Tawa M; Kopp E; McCann S; Cantrell W
Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
[TBL] [Abstract][Full Text] [Related]
17. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
Molloy K; Jonak C; Woei-A-Jin FJSH; Guenova E; Busschots AM; Bervoets A; Hauben E; Knobler R; Porkert S; Fassnacht C; Cowan R; Papadavid E; Beylot-Barry M; Berti E; Alberti Violetti S; Estrach T; Matin R; Akilov O; Vakeva L; Prince M; Bates A; Bayne M; Wachsmuch R; Wehkamp U; Marschalko M; Servitje O; Turner D; Weatherhead S; Wobser M; Sanches JA; McKay P; Klemke D; Peng C; Howles A; Yoo J; Evison F; Scarisbrick J
Br J Dermatol; 2020 Mar; 182(3):770-779. PubMed ID: 31049926
[TBL] [Abstract][Full Text] [Related]
18. Sézary syndrome managed with histone deacetylase inhibitor followed by anti-CCR4 monoclonal antibody.
Numata T; Nagatani T; Shirai K; Maeda T; Mae K; Nakasu M; Saito M; Usuda T; Tsuboi R; Okubo Y
Clin Exp Dermatol; 2018 Apr; 43(3):281-285. PubMed ID: 29327377
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma.
Muszbek N; Remak E; Xin Q; McNamara L; Jones T
J Comp Eff Res; 2023 Jul; 12(7):CER. PubMed ID: 37338181
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial.
Cowan RA; Scarisbrick JJ; Zinzani PL; Nicolay JP; Sokol L; Pinter-Brown L; Quaglino P; Iversen L; Dummer R; Musiek A; Foss F; Ito T; Rosen JP; Medley MC
J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):2225-2238. PubMed ID: 34273208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
